The Achilles heel of BCG.
There have been multiple explanations put forward to try to explain the variable efficacy of the BCG vaccine. Here I propose the new hypothesis that the primary flaw of BCG is its inability to effectively establish a population of central memory T cells. Instead, the vaccine establishes immunity represented by effector memory T cells; these distribute in the lungs and may protect humans for 10-15 years but are gradually lost. With no central memory response to compensate, the individual loses any further resistance to tuberculosis. This may have serious implications for vaccine design, given the emphasis on developing recombinant forms of BCG.
Orme
Ian M
IM
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA. ian.orme@colostate.edu
D001500:BCG Vaccine / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects* / Q000276:immunology; D008168:Lung / Q000187:drug effects* / Q000276:immunology; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000517:prevention & control*
D001500:BCG Vaccine